ELAN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 21.47%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Johnson & Johnson's return on equity of 33.27%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 11.71%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that Elanco Animal Health, Inc. has higher upside potential than Johnson & Johnson, analysts believe Elanco Animal Health, Inc. is more attractive than Johnson & Johnson.

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Johnson & Johnson's net income of $5.2B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 307.00x while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.43x versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 31.72%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Eli Lilly & Co.'s return on equity of 106.26%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 11.71%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.51%. Given that Elanco Animal Health, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Elanco Animal Health, Inc. is more attractive than Eli Lilly & Co..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 307.00x while Eli Lilly & Co.'s PE ratio is 53.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.43x versus 16.52x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 33.68%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Merck & Co., Inc.'s return on equity of 39.63%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 11.71%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that Elanco Animal Health, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Elanco Animal Health, Inc. is more attractive than Merck & Co., Inc..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 307.00x while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.43x versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 30.04%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Zoetis, Inc.'s return on equity of 52.95%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 11.71%. On the other hand Zoetis, Inc. has an analysts' consensus of $158.22 which suggests that it could grow by 26.08%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Elanco Animal Health, Inc. has a beta of 1.859, which suggesting that the stock is 85.894% more volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.841%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.59% to investors and pays a quarterly dividend of $0.50 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Zoetis, Inc.'s net income of $721M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 307.00x while Zoetis, Inc.'s PE ratio is 21.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.43x versus 5.97x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.